Cytotoxic Activity of BornUSU I towards T47D Breast Cancer Cells

Nadiya Anandita Nasution; Urip Harahap; Ginda Haro; Hari Purnomo; Denny Satria

doi:10.3889/oamjms.2019.511

Cytotoxic Activity of BornUSU I towards T47D Breast Cancer Cells

Open Access Maced J Med Sci. 2019 Nov 14;7(22):3816-3818. doi: 10.3889/oamjms.2019.511. eCollection 2019 Nov 30.

Authors

Nadiya Anandita Nasution¹, Urip Harahap¹, Ginda Haro², Hari Purnomo³, Denny Satria⁴

Affiliations

¹ Department of Pharmacology, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia.
² Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia.
³ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia.
⁴ Department of Biology, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia.

Abstract

Aim: The aim of this study was to determine cytotoxic activity of BornUSU I or Boronhafagama I (1,5-bis(4-hydroxyphenyl)-3-oxa-1,5-diaza-2,4-diboropentane-2,4-diol) as a boron derivate compounds which are boron neutron captured theraphy (BNCT) candidates.

Methods: The T47D cells were treated by BornUSU I, and Tamoxifen as a positive control. The in vitro study was using MTT method with the incubation period for 24h and 48h. All data were determined using viability of cells equation for showing each IC₅₀ value.

Results: The IC₅₀ value of BornUSU I and Tamoxifen were 72.61 ± 0.82 µM and 10.62 ± 0.06 µM for 24 h incubation period, and for the 48 h incubation period were 44.63 ± 0.23 µM and 7.79 ± 0.05 µM. The 48 h incubation period results showed the lowest IC₅₀ value.

Conclusion: The results reveal that BornUSU I provide effective as anticancer, especially for breast cancer treatment.

Keywords: BornUSU I; Breast cancer; Cytotoxicity; T47D cells.